Brief: Sensorion Announces Approval For Lead Gene Therapy Candidate Trial Of SENS-501 (OTOF-GT) In Some European Countries

Sensorion SA

19/01/2024 06:40

Jan 19 (Reuters) - Sensorion SA  ALSEN.PA :
    * ANNOUNCES APPROVAL TO INITIATE LEAD GENE THERAPY CANDIDATE
SENS-501 (OTOF-GT) INTO A PHASE 1/2 CLINICAL TRIAL IN SOME
EUROPEAN COUNTRIES
    * HAS RECEIVED APPROVAL TO INITIATE PHASE 1/2 CLINICAL TRIAL
OF
SENS-501 (OTOF-GT) IN FRANCE AS RST COUNTRY
    * CONCLUSION OF THE PART I OF THE ASSESSMENT REPORT
ACCORDING TO
REGULATION EU 536/2014 COVERING FRANCE, ITALY AND GERMANY IS
THAT THE CONDUCT OF THE CLINICAL TRIAL IS ACCEPTABLE
    * SENSORION WILL COMMUNICATE ABOUT THE RST PATIENT IN THE
COURSE
OF H2 2024

Source text for Eikon:  ID:nBw2XzxXHa 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))